Abstract
Aims
Atrial fibrillation (AF) is a major cause of morbidity and mortality. Current guidelines support performing ECG screenings to spot atrial fibrillation in high-risk patients. The purpose of this study was to validate a new algorithm aimed to identify AF in patients measured with a recent FDA-cleared contact-free optical device.
Methods and results
Study participants were measured simultaneously using two devices: a contact-free optical system that measures chest motion-vibrations (investigational device, “Gili”) and a standard reference bed-side ECG monitor (Mindray®). Each reference ECG was evaluated by two board certified cardiologists that defined each trace as: regular rhythm, atrial fibrillation, other irregular rhythm or indecipherable/missing. A total of 3582, 30-sec intervals, pertaining to 444 patients (41.9% with a history of AF) were made available for analysis. Distribution of patients with active AF, other irregular rhythm and regular rhythm was 16.9%, 29.5% and 53.6% respectively. Following application of cross-validated machine learning approach, the observed sensitivity and specificity were 0.92 (95% CI: 0.91-0.93) and 0.96 (95% CI: 0.95-0.96) respectively.
Conclusions
This study demonstrates for the first time the efficacy of a contact-free optical device for detecting atrial fibrillation.